Invenra Inc. announced a strategic collaboration with Catalent. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-d discover novel bispecific antibody-drug conjugates. Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.98 USD | -0.39% | -0.64% | +24.59% |
May. 09 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
May. 08 | Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.59% | 10.13B | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+17.21% | 239B | |
+8.01% | 204B | |
-7.57% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs